Atezolizumab is indicated as an adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells and who do not have EGFR mutant or ALK-positive NSCLC.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||18/05/2022|
|Rapid review completed||02/06/2022|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard-of-care.|